Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Sign Up to like & getrecommendations! Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2018-0210
Abstract: Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children… read more here.
Keywords: risk; anthracycline; risk benefit; cardiotoxicity ... See more keywords